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ABSTRACT
Auxiliary splicing signals play a major role in the
regulation of constitutive and alternative pre-mRNA
splicing, but their relative importance in selection
of mutation-induced cryptic or de novo splice sites
is poorly understood. Here, we show that exonic
sequences between authentic and aberrant splice
sites that were activated by splice-site mutations
in human disease genes have lower frequencies
of splicing enhancers and higher frequencies of
splicing silencers than average exons. Conversely,
sequences between authentic and intronic aberrant
splice sites have more enhancers and less silencers
than average introns. Exons that were skipped as
a result of splice-site mutations were smaller, had
lower SF2/ASF motif scores, a decreased availability
of decoy splice sites and a higher density of
silencers than exons in which splice-site mutation
activated cryptic splice sites. These four variables
were the strongest predictors of the two aberrant
splicing events in a logistic regression model.
Elimination or weakening of predicted silencers in
two reporters consistently promoted use of intron-
proximal splice sites if these elements were main-
tained at their original positions, with their modular
combinations producing expected modification of
splicing. Together, these results show the existence
of a gradient in exon and intron definition at the
level of pre-mRNA splicing and provide a basis for
the development of computational tools that predict
aberrant splicing outcomes.
INTRODUCTION
Removal of introns from pre-messenger RNA
(pre-mRNA) by splicing is a critical step in eukaryotic
gene expression. Splicing of human pre-mRNAs is
mediated by conserved but highly degenerate sequences
at the splice sites. These signals include the YAG|R
consensus (Y is pyrimidine, R is purine, | is the intron/
exon boundary) at the 30 splice site (30ss), with upstream
poly-Y tracts (PPTs) and the branch point sequence
(BPS), and the MAG|GURAGU consensus (M is A or C)
at the 50 splice site (50ss). In addition to these essential
sequences, accurate recognition of exons and introns by
the spliceosome requires auxiliary signals that repress or
promote splicing, termed exonic or intronic splicing
silencers (ESSs/ISSs) or enhancers (ESEs/ISEs). These
elements are thought to act as binding sites for splicing
factors, which comprise serine/arginine-rich (SR) proteins
(1) or heterogeneous nuclear ribonucleoproteins
(hnRNPs) (2–5). Apart from direct contacts with trans-
acting factors, ESSs, ISSs, ESEs and ISEs may inﬂuence
splicing through alterations of the RNA secondary
structure by modifying their access to the pre-mRNA or
their interactions with each other (6).
Auxiliary splicing sequences have been characterized by
in vivo or in vitro selection methods (1,7–10) or through
disease-associated mutations or variants that disrupted
pre-mRNA splicing (11,12). In addition to experimental
approaches, these elements have been identiﬁed ab initio
by comparing oligomer frequencies between exons and
introns and between exons with weak and strong splice
sites (hexamer RESCUE-ESEs) (13), between non-coding
exons and pseudoexons plus the 50 untranslated region
(UTR) of intron-less genes (putative octamer ESEs/ESSs
or PESEs/PESSs) (14,15), or by evaluating conservation
levels of exonic wobble positions (16). However, the
relative importance of these signals in selection of 50 or 30ss
and regulation of alternative splicing has been poorly
understood.
Naturally occurring mutations or DNA variants that
aﬀect pre-mRNA splicing represent a substantial propor-
tion of gene alterations leading to Mendelian disorders
(17,18) and are thought to contribute signiﬁcantly to
predisposition to or protection against multifactorial
or complex traits (19,20). Disease-associated splicing
mutations usually lead to skipping of one or more exons
or to activation of cryptic (if the mutation is in the
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elsewhere) splice sites (21–25). Activation of cryptic
splice sites can be inﬂuenced by the balance between
the intrinsic strength of aberrant splice sites and their
authentic counterparts (23–27), the availability of tradi-
tional splicing signals in the vicinity of mutated splice sites
(18,28), exon and intron size (29), the nature of mutation
(24,25) and by disrupting or creating ESEs, ESSs, ISEs or
ISSs. Although exon skipping and cryptic/de novo splice-
site activation account for the vast majority of aberrantly
spliced RNA products transcribed from mutated alleles,
the extent to which these cis-elements contribute to activa-
tion of mutation-induced splice sites has not been systema-
tically investigated. Moreover, comparative signiﬁcance of
factors that determine which of the two aberrant splicing
outcomes takes place is unknown.
In the present study, we have examined the frequency of
computationally predicted ESEs and ESSs in a compre-
hensive set of 518 human sequences located between
mutation-induced aberrant splice sites and their authentic
counterparts. In addition, we have ascertained sequences
of 250 exons that were excluded from mature transcripts
as a result of disease-associated splice-site mutations and
sequences of mutation-induced pseudoexons that were
activated de novo in introns. We have compared these
sequences to a set of controls that included intronic
sequences that were never spliced, conserved exons, alter-
natively spliced exons and non-coding exons. In addition,
we have compared sequences of the skipped exons
with exons that sustained aberrant splice-site activation
in vivo to identify factors that best predict the two
pathological splicing outcomes. Furthermore, we have
used two splicing reporter systems to experimentally test
whether predicted ESSs between competing 30ss consis-
tently repress usage of intron-proximal sites and how their
modular combinations inﬂuence 30ss selection. Finally,
using the human proinsulin gene as a model, we show how
ESS mutations capable of reducing or increasing canoni-
cal transcripts alter the expression of the resulting peptide.
MATERIALS AND METHODS
Ascertainment of nucleotide sequences
Sequences between mutation-induced aberrant 30ss and
their authentic counterparts were obtained from the
updated version of DBASS3, the database of aberrant
30ss in human disease genes (24). Sequences between
aberrant 50ss and their authentic counterparts were
acquired from the recently published sister database of
mutation-induced aberrant 50ss, termed DBASS5 (25).
These sequences and their annotations are available from
the DBASS5 and DBASS3 web site at http://www.dbass.
org.uk. Aberrant splice sites were both in exons (E) and
introns (I) and were generated by mutations within
(cryptic, CR) or outside (de novo, DN) 50 or 30ss consensus
sequences in 264 human disease genes, leading to  250
recognizable phenotypes. The resulting sequence cate-
gories were designated CR-E, DN-E, CR-I and DN-I
(Figure 1). The total number of non-repetitive aberrant
50 and 30ss (including pseudoexons) was 305 and 258,
respectively, with 276 located in introns and 287 in exons.
In addition to aberrant splice sites, we collected
sequences of 250 human exons that were skipped as a
result of disease-causing mutations in natural splice sites
of 127 genes (EXSK; Figure 1 and Table S1). These
sequences were obtained by searching the ‘Human Gene
Mutation Database’ and ‘PubMed’ for exon skipping
events reported in hereditary diseases and by comparing
the information in the literature to the integrated human
genome databases through the ‘Ensembl’ web site. Inclu-
sion criteria for such exons were as follows: (i) splice-site
mutations were shown to be disease-causing or pre-
disposing; (ii) exon skipping was detected either in
patients’ RNA samples or in splicing reporter assays
following transfection of wild-type and mutated con-
structs into mammalian cell lines, but not in controls;
(iii) aberrant transcripts were characterized by nucleotide
sequencing and (iv) there was no obvious utilization of
aberrant splice sites in the exon or adjacent introns.
Similarly, we analysed sequences of human pseudo-
exons (PS) that were included in mature transcripts as
Figure 1. Schematic representation of sequence categories. Primary
transcripts are shown as exons (boxes) and introns (lines). Exonic or
intronic sequences analysed in this study are shown as blue boxes or
blue thick lines, respectively. Canonical and aberrant splicing events are
shown above and below primary transcripts, respectively. Disease-
associated splicing mutations are schematically shown as red stars.
Designation of each sequence category and corresponding numbers of
analysed sequences is above and below the primary transcript,
respectively. Arrows denote translation initiation sites. CR-E, sequences
between cryptic splice sites in exons and their authentic counterparts;
DN-E, sequences between de novo splice sites in exons and their
authentic counterparts; CR-I, cryptic splice sites in introns; DN-I,
de novo splice sites in introns; PS, sequences of mutation-induced
pseudoexons (Table S2); EXSK, sequences of exons that were skipped
as a result of splice-site mutations leading to disease phenotypes
(Table S1); IN-PS, intronic sequences that have strong 30ss and 50ss and
a size of 50–250nt, but were never used by the spliceosome (14);
HM-EX, human exons homologous to mouse exons (30); ALT-EX,
alternatively spliced human exons (30); NC-EX, non-coding exons
lacking protein-coding information (14); 50-UTR-IL, sequences of
50UTR in intron-less genes (14). The total length of the sequence
categories (in nucleotides, nt) was 10383; 7862; 10686; 6988; 6114;
29292; 352688; 5817754; 513162; 50187 and 245076, respectively.
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(n=13) or de novo 50ss (n=32; Figure 1, Table S2). All
these sequences were compared to controls that included
human exons homologous to murine exons (HM-EX),
alternatively spliced exons (ALT-EX) (30), intronic
sequences that were ﬂanked by strong splice sites but
were never spliced (‘intronic pseudoexons’, IN-PS),
non-coding exons (NC-EX) and intron-less sequences in
the 50-UTR (50-UTR-IL), as described (14). Schematic
representation of these sequences and their number in
each category is shown in Figure 1.
Analysis ofauxiliary splicing sequences
Sequences in each group were used as input ﬁles for
publicly available ESE/ESS prediction algorithms at
http://genes.mit.edu/burgelab/rescue-ese/(RESCUE-ESEs)
(13,31), http://genes.mit.edu/fas-ess/(ﬂuorescence-activated
screen or FAS-ESSs) (10,32) and http://cubweb.biology.
columbia.edu/pesx/(PESEs and PESSs) (14,15). In addi-
tion, we have used the ESEﬁnder (v. 3.0) (33,34) available
at http://rulai.cshl.edu/tools/ESE to examine ESE motifs
of four SR proteins.
The number of ESSs/ESEs in each sequence was
obtained by counting each individual site that falls entirely
or mostly in the sequences of mutated (sequence groups
shown in the left panel of Figure 1 plus EXSK) or wild-
type (right panel plus 50-UTR-IL) alleles. Speciﬁcally,
input sequences between cryptic and authentic splice site
had an extra three (RESCUE-ESEs and FAS-ESSs)
or four (octamer PESEs/PESSs) ﬂanking nucleotides.
To obtain the ESS/ESE density, the total number of
predicted ESSs/ESEs was divided by the sequence length
(in nucleotides) that excluded 3- or 4-nt overhangs and
this ﬁgure was multiplied by 100. For comparison of
EXSK and CR-E exons and logistic regression analysis,
input exon sequences were devoid of ﬂanking nucleotides
to minimize possible confounding eﬀects from 30 and 50ss
signal sequences. Similarly, to determine the density of
ESE motifs for SF2/ASF, SC35, SRp40 and SRp55 and
their score densities, we divided their number and the sum
of their scores in each sequence by its length in nucleotides
and multiplied by 100. Threshold values for the original
SF2/ASF (34), the updated (IgM-BRCA1) SF2/ASF
version (33), SC35, SRp40 and SRp55 ESE motifs were
1.956, 1.867, 2.383, 2.67 and 2.676, respectively. The ESE
motifs with scores above these standard thresholds are
considered to be signiﬁcant (33,34).
Splice-site prediction
The number of decoy 30 and 50ss in EXSK and CR-E
exons was determined using the machine-learning neural
network (NN) model as described (35). We used the
NN splice-site predictor (v. 0.9) available at http://www.
fruitﬂy.org/seq_tools/splice.html. To obtain the NN score
density, we calculated the total number of predicted splice
sites with NN scores of 0.001 and higher, divided this
ﬁgure by the sequence length in nucleotides and multiplied
by 100. The value of 0.001 was arbitrary to increase the
power of our comparison, because many aberrant splice
sites with NN scores 0.4 (default) or lower are eﬃciently
used in vivo.
In addition to splice-site prediction ab initio, we used
the maximum entropy (ME) model (36) to estimate the
intrinsic strength of splice sites in most sequence cate-
gories. These scores were computed as described (24,25)
using online tools available at http://genes.mit.edu/burge
lab/maxent/Xmaxentscan_scoreseq_acc.html. The ME
scores were shown to discriminate best aberrant 30 (24)
and 50ss (25) from their authentic counterparts. In
addition, we determined the Shapiro and Senapathy
(S&S) matrix scores in EXSK and our wild-type and
mutated reporter constructs. The S&S scores are based
on the nucleotide frequency matrix at 30 and 50ss and
assume independence between individual positions of
splice-site consensus sequences (37,38). The S&S scores
were computed using an online tool available at http://
ast.bioinfo.tau.ac.il/SpliceSiteFrame.htm.
Statistical analysis
To model the relationship between predictor variables
and the dichotomous splicing outcome (exon skipping and
aberrant splice-site activation), we used step-wise and
logistic regression analyses in S-PLUS (v. 7.0, Insightful
Corp., USA). The S-PLUS was also employed to compare
logistic regression models containing four to seven inde-
pendent variables. To test whether there are signiﬁcant
diﬀerences in the mean ESE/ESS densities among
sequence categories, we used the Kruskal–Wallis analysis
of variance (ANOVA) on ranks in the same statistical
package, followed by the Dunn’s test, a non-parametric
version of the Holm–S ˇ ida ´ k multiple comparison test.
Multiple comparisons of ESE/ESS proportions were
carried out using the Marascuilo procedure implemented
in XLSTAT (v. 2007.6; Addinsoft).
Splicingreporter constructs
Plasmids containing the entire gene for human proinsulin
(INS) were prepared by amplifying a 1.5kb genomic
fragment with primers E1 (50-ag ccc tcc agg aca ggc t)
and R1 (50-ttc aag ggc ttt att cca). The amplicons were
cloned into the mammalian expression vector pCR3.1
(Invitrogen) and validated by sequencing. Minigenes
containing exons 1 through 3 of the human gene for
hepatic lipase (LIPC) were described previously (27).
Mutated constructs were prepared with overlap-extension
PCR as described (39). Plasmids were propagated in
Escherichia coli DH5a and puriﬁed using the Wizard Plus
SV Minipreps kit (Promega). Sequences of all constructs
were analysed with the ESS/ESE prediction algorithms
as described above.
Cellculture, transfections and detection of RNA products
Human embryonic kidney 293T cells were grown under
standard conditions in RPMI1640 supplemented with
10% (v/v) fetal calf serum (Gibco BRL). Transient trans-
fections were performed in 6- or 12-well plates using
siPORT XP-1 (Ambion) according to the manufacturer’s
recommendations. Total RNA was isolated using TRI
Reagent (Ambion) 48h post-transfection and treated with
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transcribed using oligo(dT)15 primers and Moloney
murine virus reverse transcriptase (RT; Promega).
RT-PCR products were ampliﬁed with primers directed
to vector sequences and, as a validation control for the
ratios of RNA products, with a combination of cDNA
and vector primers as described (20). Exon inclusion levels
were measured as described (40). The identity of each
RNA product was conﬁrmed by sequencing.
Measurementof proinsulin production
Proinsulin levels were measured in culture supernatants of
293T cells transfected with equimolar amounts wild-type
INS and two mutated constructs, in which ESS/ESE
mutations did not alter any amino acids (20). Total
proinsulin was quantiﬁed by dissociation-enhanced
lanthanide ﬂuoroimmunoassay using monoclonal anti-
bodies 3B1 and CPT3F11 as described (20).
RESULTS
Contributionof auxiliary splicing sequences toactivation
ofmutation-induced aberrant splice sites
To characterize auxiliary signals underlying aberrant
splice-site activation, we examined sequences located
between mutation-induced cryptic (CR) or de novo (DN)
splice sites in exons (E) and introns (I) and their authentic
counterparts (24,25). In addition, we collected and
analysed sequences of exons that sustained splice-site
mutations and were skipped without activating any
aberrant splice site (Table S1) and pseudoexons that
were activated by intronic point mutations (Table S2).
These sequences (designated CR-E, DN-E, CR-I, DN-I,
EXSK and PS, respectively; Figure 1) were compared to
controls that included human-mouse conserved exons
(HM-EX), alternatively spliced exons (ALT-EX) (30),
non-coding exons (NC-EX), 50-UTR of intron-less genes
(50-UTR-IL) (14) and intronic segments that were ﬂanked
by strong splice sites but never included in mature
transcripts (‘intronic pseudoexons’, IN-PS; Figure 1) (14).
We ﬁrst determined the total number of computation-
ally predicted ESSs/ESEs in each sequence category,
divided their counts by the entire nucleotide length and
multiplied by 100 to obtain the ESS/ESE densities
(Figures 2 and S1A). Exonic segments between cryptic/
de novo splice sites and their authentic counterparts that
were excluded from the mRNA as a result of splice-site
mutations (CR-E and DN-E) had signiﬁcantly higher
PESS and FAS-ESS densities than conserved human
exons (HM-EX), but lower than average introns (IN-PS;
Table S3). Conversely, CR-E/DN-E segments had a lower
density of PESEs and RESCUE-ESEs than HM-EX and
a higher density of PESEs than IN-PS. On the other hand,
newly exonized intronic segments ﬂanking authentic
splice sites (CR-I and DN-I) had a higher density of
PESEs and lower PESS and FAS-ESS densities than
IN-PS. More stringent sets of PESSs (the I and P scores
lower than  2.88) (14) and the FAS-ESS hex3 set (10)
revealed similar diﬀerences (Figure S1A). The diﬀerence
in the RESCUE-ESE density between IN-PS and
CR-E/DN-E or CR-I/DN-I was not strictly signiﬁcant,
which was partly attributable to a low number of these
signals in Y-rich sequences upstream of 30ss.
In addition to ESE/ESS densities, we divided ESE/ESS
counts in each input sequence by its length to obtain the
mean ESE/ESS densities. The diﬀerences in the median
values of these densities among the sequence categories
were signiﬁcantly greater than expected by chance
(P<10
 10 for each signal; Kruskal–Wallis ANOVA on
ranks). The Dunn’s test carried out with conserved exons
(HMEX), exonic sequences excluded from mRNAs,
exonized intronic segments and introns (Figure S2)
revealed signiﬁcant diﬀerences for most pair-wise compar-
isons, with an increasing (ESS) and decreasing (ESE)
exon-to-intron gradient. Thus, the newly created exonic
and intronic sequences had ESE/ESS levels intermediate
between average introns and conserved exons, indicating
that auxiliary signals contribute extensively to selection
of mutation-induced aberrant splice sites.
Characterization of compensatorysignals that promote
activation ofcryptic splice sitesin exons
To investigate a relationship between ESEs/ESSs and
traditional splice-site recognition sequences in each
Figure 2. Density of auxiliary splicing signals in each sequence
category. Grey/red bars represent the total number of ESEs/ESSs in
each sequence category divided by the total length of sequence group
and multiplied by 100. Designation of sequence categories is the same
as in Figure 1. (A) Density of PESE and PESS octamers (14).
(B) Density of RESCUE-ESEs (13) and FAS-ESSs (32).
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intrinsic strength as the average ME scores. Updated
DBASS3/5 data conﬁrmed (24,25) that cryptic splice
sites in exons are exceptionally weak as compared to
their authentic counterparts (Figure 3A–D), yet they were
eﬃciently used in vivo, indicating that their activation
requires auxiliary elements. To test this requirement in
more detail, we compared the increase or decrease of
each ESS/ESE density over HMEX in CR-E and DN-E
(Figure 3E). The two categories show a marked diﬀerence
(ME) in the mean ME scores between authentic and
aberrant splice sites in exons. For aberrant 30ss, higher
MEs in CR-E were accompanied by a greater increase of
the FAS-ESS and PESS densities and a greater decrease in
the PESE density in CR-E than in DN-E. In contrast,
intrinsically weaker cryptic 50ss had a greater decrease of
the RESCUE-ESE density than de novo 50ss. This suggests
that activation of cryptic 30 and 50ss in exons is facilitated
by diﬀerential requirements for ESE/ESS signals, with
FAS-ESSs and PESXs promoting more cryptic 30ss and
RESCUE-ESEs cryptic 50ss. However, the compensatory
increase or decrease of their levels over conserved exons
cannot alone explain the intrinsic weakness of CR-E
or their high MEs (Figure 3A, C and D), indicating that
activation of cryptic splice sites in exons, particularly 50ss,
requires additional help.
SRESEmotiffrequenciesinnewexonicandintronicsegments
To test whether the observed diﬀerences in the ESE
densities are reﬂected in alterations of putative ESE motifs
for SR proteins (SR ESEs), we used the ESEﬁnder (34) to
determine the SR ESE densities for SF2/ASF, SC35,
SRp40 and SRp55 and their average scores in each
sequence group. Of the four SR proteins, the updated
score matrix of SF2/ASF (33) showed the largest spread
across sequence categories ( 72%; Figure 4A), ranging
from the lowest values in average introns (IN-PS), via
newly included (PS) or excluded (EXSK) sequences from
mRNAs, via weakly spliced (ALT-EX), conserved
(HM-EX) and non-coding (NC-EX) exons and, ulti-
mately, to pre-existing exons that were extended (CR-I)
Figure 3. Predicted eﬀect of ESSs on selection of cryptic and de novo
splice sites in each sequence category. Designation of sequence
categories and schematic representation of exons, introns and aberrant
transcripts is the same as in Figure 1. Putative strong (red) or weak
(pink) ESSs are schematically shown as boxes between cryptic (A,C)
or de novo (B,D) splice sites and their authentic counterparts. Location
of aberrant splice sites is shown on the right. Their expected inhibitory
or stimulatory eﬀects on competing splice sites are shown by the minus
and plus signs, with weak and strong eﬀects denoted by thin and thick
arrows, respectively. The mean maximum entropy (ME) scores (36) for
canonical and aberrant splice sites in each category are shown above
and below the primary transcript, respectively. The updated ME scores
were computed for 305 aberrant 30ss (A,B) and 258 aberrant 50ss (C,D)
and their authentic counterparts as described (24,25). (E) Comparison
of the intrinsic strength of aberrant splice sites in exons with the ESS/
ESE densities. ME is the diﬀerence in the mean ME scores between
authentic and aberrant splice sites. The mean scores are shown in
panels A–D. The increase [PESS (I and P score < 2.62) and FAS-ESS
(hex 2 set)] or decrease [PESE (I and P score 2.62) and RESCUE-
ESE] of ESE/ESS densities in CR-E/DN-E segments over conserved
exons is shown as a percentage for each sequence category.
Figure 4. Control of aberrant splice-site activation by predicted
SF2/ASF ESE motifs. (A) A rainbow gradient of SF2/ASF-mediated
exon/intron deﬁnition. The SF2/ASF ESE score density (IgM-BRCA1
version) was calculated as a sum of SF2/ASF ESE scores in each
sequence group, divided by the sequence length and multiplied by 100.
Each category is denoted by a colour shown on the right. Sequence
categories were ordered from the highest score density to the lowest.
For HM-EX and ALT-EX, only 1000 randomly selected sequences
were analysed due to size limitations of the server. (B) The SR ESE
motif densities in aberrant 50ss. Each SR protein is represented by
a colour shown on the right side.
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of the ASF/SF2 ESE densities showed signiﬁcant diﬀer-
ences between IN-PS and both CR-E/CR-I and CR-E/
DN-I, as well as among other groups (Table S4). Non-
parametric ANOVA with mean SF2/ASF ESE score
densities followed by the Dunn’s test also discriminated
segments excluded from mRNAs from both conserved
exons and introns (data not shown). Importantly, the
highest SF2/ASF score density was observed in CR-E
segments (Figure 4A), indicating that activation of exonic
cryptic splice sites relies on signiﬁcant SF2/ASF help.
The greatest diﬀerence in the ordered SF2/ASF ESE score
densities for adjacent sequence groups was between loss of
the entire exon (EXSK) and gain of the entire exon (PS)
(Figure 4A). CR-E showed the highest density also for
SC35 and SRp55, but not for SRp40, suggesting that
SC35 and SRp55 promote selection of cryptic splice sites
in exons to a lesser extent (data not shown). SRp40 had
the smallest ﬂuctuations ( 19%) among the sequence
categories.
The SR ESE density was signiﬁcantly higher in 50ss
CR-E sequences than in 50ss DN-E segments (P=0.04).
This diﬀerence was similar for the SR ESE score densities
(data not shown) and was mainly due to SF2/ASF
ESEs (P=0.002 for the original SF2/ASF score matrix
and 0.004 for the IgM-BRCA1 matrix; Figure 4B). For
sequences between aberrant 30ss and their authentic
counterparts, we observed no signiﬁcant diﬀerences,
but their number was lower and their total sequence
length was smaller than corresponding categories of 50ss
(Figure 1).
ESS/ESEfrequencies in mutation-induced pseudoexons
areintermediate between exons and introns
Next, we examined both traditional and auxiliary splicing
sequences of cryptic exons or pseudoexons (PS; Figure 1)
that were included in the mRNA as a result of intronic
mutations creating de novo 50 and 30ss. The ME scores of
splice sites created by activating mutations were signiﬁ-
cantly higher than those on the opposite ends of
pseudoexons, both for mutations giving rise to the 50ss
(Wilcoxon–Mann–Whitney sum rank test; P=0.02) and
the 30ss (P=0.01; Figure 5). In addition to a higher PESE
density in PS than in average introns, PS sequences had
also an elevated RESCUE-ESE density as compared to
IN-PS (Figure 2A and Table S3). Conversely, the densities
of both types of silencers were lower in PS than in IN-PS.
In contrast, comparison of PS and HM-EX showed
a higher PESS and a lower PESE density in PS. Finally,
the SF2/ASF ESE score density in PS was also inter-
mediate between HM-EX and IN-PS (Figure 4A and
Table S4). The same tendency was observed for SC35 and
SRp55, with the PS levels consistently the second lowest
of all sequence categories, but the second highest for
SRp40 (data not shown).
Exonsthat were skipped as aresultof splice-site mutations
areweaker thanaverage exons
The median length of 250 exons that were skipped without
activating any cryptic sites (EXSK) was signiﬁcantly lower
than the median size of the average exon (109 versus
122nt, P<0.001), but similar to a median of ALT-EX
(112nt). The most pronounced size diﬀerence between
EXSK and HM-EX was observed for  40–75nt exons
that created a second peak in the frequency distribution
(Figure 6A).
The mean ME scores of the wild-type EXSK 50ss was
similar to those of conserved human exons (data not
shown), but the ME scores of the wild-type EXSK 30ss
were signiﬁcantly lower than 30ss of HM-EX (P=0.04)
and still somewhat lower than ALT-EX 30ss even though
most mutations leading to exon skipping were in the 50ss
(Figure 6B). Comparison of the S&S scores showed a
similar tendency, but the P-value was higher (P=0.14),
most likely due to the superiority of the ME algorithm
over S&S (24,25).
Because position  3 relative to the intron/exon bound-
ary is conserved and shows a C T>A>G hierarchy in
the splicing eﬃciency (41), we determined nucleotide
frequencies at this position in introns that precede skipped
exons. The frequency of As was not signiﬁcantly diﬀerent
from that calculated for introns preceding HM-EX
exons (4.8% versus 5.5%, respectively), suggesting that
the diﬀerential strength of 30ss is determined by upstream
sequences, most likely by the PPT.
The PESE density was lower and the PESS density
higher in EXSK than in conserved exons (Figures 2A and
S1; Table S3). Although the RESCUE-ESE density was
slightly lower in EXSK than in HM-EX (Figure 2B), the
P value did not reach the 5% signiﬁcance level in multiple
comparisons (Table S3). The PESX and FAS-ESS
densities for ALT-EX were intermediate between EXSK
and HM-EX, with RESCUE-ESE densities in EXSK and
ALT-EX virtually identical (Figure 2B).
The observed higher densities of ESSs, which are
oligomers characterized by high uracil (U) content, was
reﬂected in  9% U increase in EXSK over HM-EX
Figure 5. Pseudoexon splice sites created by intronic mutations are
strong. The average ME scores of splice donor (black bars) and
acceptor (grey bars) sites of pseudoexons that were activated by
mutations in 50ss (left panel) or 30ss (right panel). Error bars represent
standard deviations.
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ences in other nucleotides between the two groups were
much smaller, including As, which are markedly increased
in RESCUE-ESEs as compared to background sequences
of RefSeq pre-mRNAs, and Gs, which are enriched in
FAS-ESSs (Figure S1B).
Dissection of factorsthat determine mutation-induced
exon skippingand cryptic splice-site activation
To begin to disentangle the relation between multiple
factors that determine the two aberrant splicing outcomes
and to develop an initial predictive model, we compared
sequences of exons, in which splice-site mutations
activated cryptic splice sites (CR-E exons), with exons in
which splice-site mutations led to exon skipping (EXSK;
Table 1). Apart from a larger size of CR-E exons
(P<0.001; Wilcoxon–Mann–Whitney sum rank test),
the CR-E exons had a signiﬁcantly higher NN score
density of predicted splice sites (P=0.001). The NN score
density of predicted 50ss contributed more to this diﬀer-
ence than predicted 30ss (P=0.002 and P=0.07, respect-
ively). Importantly, the PESS density in CR-E exons was
signiﬁcantly lower than in EXSK in multiple comparisons
while the PESE and RESCUE ESE densities showed only
small variations (Table 1). The CR-E exons had also a
signiﬁcantly higher number of SR SF2/ASF ESEs and
a higher SF2/ASF score densities than EXSK (Table 1).
Unlike the RESCUE-ESE density, the SF2/ASF ESE
density in CR-E was higher than in the average exon
(Figures 2 and 4A), pointing to a potentially important
dichotomy of RESCUE-ESEs and SR ESEs as these
elements do not overlap with each other beyond what is
expected by chance (42). In multiple comparisons, the
entire CR-E exons had signiﬁcantly higher PESE and
RESCUE-ESE densities and lower PESS and FAS-ESS
than CR-E segments. However, unlike the CR-E seg-
ments, the ESS densities in the CR-E exons and HM-EX
were similar, with the ESE densities only marginally lower
in CR-E exons (Figure 2 and Table 1, and data not
shown). This strongly suggests that it is largely the
sequence between authentic and aberrant splice sites that
determines whether the splicing outcome is exon skipping
or aberrant splice-site activation.
Comparison of SF2/ASF ESE densities in CR-E exons
with HM-EX and EXSK showed that CR-E exons had
the highest density, followed by HM-EX and EXSK
(Figure 7). As with CR-E and DN-E segments
(Figure 4B), the SF2/ASF ESE density was signiﬁcantly
higher in CR-E exons containing cryptic 50 than 30ss, with
the latter exhibiting levels similar to conserved exons, but
still somewhat higher than EXSK. Thus, the increase of
predicted functional SF2/ASF sites in exons with cryptic
splice sites over conserved exons is driven by 50ss.
To model the relationship between predictor variables
shown in Table 1 and the two aberrant splicing outcomes,
we used multiple logistic regression with the mean ESE/
ESS/SR ESE densities and their scores, exon length and
the mean numbers of predicted splice sites and means of
their NN scores. Binomial maximum likelihood estimates
showed that the increased exon length was the best
predictor of aberrant splice-site activation, followed by
the mean SF2/ASF ESE score density, the density of NN
scores for 50ss and the mean PESS density (Table 2).
Combining PESE and RESCUE-ESE densities into a
single predictor variable did not reach signiﬁcant P-values
in regression analyses. Finally, employing the density of
NN scores for both 30 and 50ss and the combined density
of FAS-ESS and PESS, exon length was still the best
predictor variable, followed by the SF2/ASF ESE score
density, the combined 30 and 50 NN score density and the
combined FAS-ESS and PESS density.
Consistent inhibition of intron-proximal 3’ss
by predicted FAS-ESSs
A systematic introduction of FAS-ESS sequences
between competing 30 or 50ss consistently inhibited usage
Figure 6. Exons that were skipped as a result of splicing mutations are
shorter than average exons and have weak 30ss. (A) Length distribution
of 250 skipped exons (EXSK). The observed distribution is shown as
black bars. The expected distribution (grey bars) was calculated for the
same number of exons using exon sizes of 43244 homologous human-
mouse exons (30). (B) Comparison of the intrinsic strength of 30ss
between exons that were skipped as a result of splice-site mutation
(EXSK), and conserved (HM-EX) and alternatively spliced exons
(ALT-EX). Grey bars represent means; error bars denote standard
deviations; horizontal lines with labels are medians.
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in agreement with the observed higher FAS-ESS levels
in CR-E/DN-E than in exons and with their lower levels in
CR-I/DN-I than in introns (Figure 2 and Table S3).
Stronger FAS-ESS in CR-E/DN-E would promote
activation of cryptic splice sites and weaker FAS-ESS in
CR-I/DN-I would promote activation of de novo splice
sites (Figure 3A–D). However, a comparative analysis
based on the conservation level of wobble positions in
human and mouse orthologous exons suggested position-
dependency of splicing regulatory sequences (16). To test
the generality of these ﬁndings, we examined naturally
occurring ESS/ESE motifs between competing 30ss in
human genes coding for proinsulin (INS; Figure 8) and
hepatic lipase (LIPC; Figure 9).
The wild-type INS reporter activates a strong cryptic
30ss in exon 3, 126nt downstream of authentic 30ss
(Figure 8). We prepared a series of constructs with muta-
tions in predicted FAS-ESSs and other motifs (Figure 8B
and C), transfected mutated and wild-type plasmids
into 293T cells and examined their splicing pattern
(Figure 8D). Mutations were designed to avoid creation
or elimination of other computationally predicted ESSs/
ESEs, except for clones 11 and 13. None of the introduced
changes created termination or initiation codons, nor did
they create optimal splice-site consensus sequences pre-
dicted to be recognized by translation or spliceosome
machineries. Clone 2, which lacked strong overlapping
FAS-ESSs with a run of four Gs, showed a markedly
Table 1. Comparison of exonic sequences that were excluded from mRNAs owing to mutations activating (CR-E exons) or failing to activate
(EXSK) cryptic splice sites
Sequence category CR-E exons
a EXSK CR-E exons/EXSK
Median (mean) length in nucleotides 148 (164.8) 109.5 (117.2) 1.35 (1.41)
Number of predicted splice sites with NN scores >0.001 (per 100nt) 998 (3.50) 881 (3.01) 1.16
Sum of NN scores in predicted splice sites (per 100nt) 142.6 (0.50) 104.4 (0.36) 1.39
Number of PESSs with I and P scores less than  2.62 (per 100nt) 313 (1.10) 516 (1.76) 0.63
Number of PESEs with I and P scores over 2.62 (per 100nt) 1882 (6.60) 1775 (6.06) 1.09
Number of PESSs with I and P scores less than  2.88 (per 100nt) 203 (0.71) 342 (1.17) 0.61
Number of PESEs with I and P scores over 2.88 (per 100nt) 1502 (5.27) 1423 (4.86) 1.08
Number of hex2 FAS-ESSs (per 100nt) 907 (3.18) 960 (3.28) 1.03
Number of hex3 FAS-ESSs (per 100nt) 531 (1.86) 534 (1.82) 0.98
Number of RESCUE-ESEs (per 100nt) 2633 (9.23) 2851 (9.73) 0.95
Number of SF2/ASF ESEs (per 100nt) 1204 (4.22) 957 (3.27) 1.30
Number of SF2/ASF (IgM-BRCA1) ESEs (per 100nt) 1698 (5.96) 1366 (4.66) 1.28
The average SF2/ASF ESE score per 100nt 12.67 9.66 1.32
The average SF2/ASF (IgM-BRCA1) ESEs per 100nt 16.92 12.92 1.31
Number of SC35 ESEs (per 100nt) 1254 (4.40) 1198 (4.09) 1.08
Number of SRp40 ESEs (per 100nt) 1203 (4.22) 1211 (4.13) 1.02
Number of SRp55 ESEs (per 100nt) 732 (2.57) 689 (2.35) 1.09
Number of all SR ESEs (per 100nt) 6091 (21.36) 5421 (18.51) 1.15
Sum of all SR ESE scores (per 100nt) 19440.2 (68.18) 17240.8 (58.86) 1.16
aCR-E exonic sequences were obtained by extending the CR-E sequences [Figure 1 and ref. (24,25)] to cover the whole exon. Each exon was
manually matched to the Ensembl exon–intron structure (www.ensembl.org). Only non-repetitive CR-E exons were analysed, totalling to 28512
nucleotides. All input CR-E exon and EXSK sequences were devoid of ﬂanking nucleotides to minimize possible confounding eﬀects from 30 and 50ss
signal sequences.
Figure 7. The SF2/ASF ESE density in exons activating cryptic 50 and
30ss, in skipped exons and conserved human exons. Dark and light grey
bars denote the total number of original SF2/ASF and updated
SF2/ASF ESE motifs per 100nt, respectively.
Table 2. Multiple regression model to predict aberrant splice-site
activation and exon skipping
Predictor variable Regression
coeﬃcient
Standard
error
t-value P-value
Exon length 0.0092 0.0017 5.36 <0.0001
SF2/ASF ESE
score density
a
0.0535 0.0179 2.99 <0.005
The NN score
density (50ss)
0.9679 0.3258 2.97 <0.005
PESS density 0.1365 0.0673 2.03 <0.05
Input data for logistic regression summarized in Table 1 were analysed
using a generalized linear model with a logistic link (S-PLUS, v. 7.0).
aThe original SF2/ASF matrix was a consistently preferred variable
over the updated (33) matrix in both stepwise and logistic regression
analyses. Correlation of the two densities in EXSK and CR-exons
was 0.77.
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GG>CC in clone 3, which also removed a PESE
CTGGAGGG, had a similar eﬀect. Splicing to canonical
30ss was improved less in clone 4, in which the most distal
FAS-hex2 ESS was eliminated. Clones 5 and 6 had double
mutations in FAS-ESSs between competing cryptic 30ss
and also showed a signiﬁcant decrease in the utilization
of cryptic 30ss. Clone 6 as well as clone 11 (see below)
promoted use of a minor cryptic 30ss 74nt downstream
of authentic 30ss. This eﬀect was most likely due to
Figure 8. FAS-ESS-mediated inhibition of authentic 30ss of INS intron 2 and its eﬀects on proinsulin production. (A) INS construct. Primary
transcripts are represented by exons (boxes) and introns (lines). The length of each intron and exon is shown above the primary transcript
(in nucleotides). Canonical and alternative splicing is denoted by dotted lines above and below the pre-mRNA, respectively. RNA products
containing exon 2 are numbered 3–6 as described previously (20). For simplicity, RNA isoforms 1 and 2 are not shown as they are expressed in very
low levels. An exonic segment between two competing 30ss is shown in blue. (B) Multiple alignment of human (h), chimpanzee (c), mouse (m) and rat
(r) sequences and computationally predicted auxiliary splicing elements. Intron 2 is shown in lowercase, exon 3 is in upper case. Black asterisks
denote nucleotides shared between the species. A red star shows a G/T variant in a predicted human-speciﬁc FAS-ESS. Alternative 30ss at exon
position +36 and +74 are shown by arrows. FAS-ESSs (10,32) are in red, RESCUE-ESEs (13,31) are in blue, PESEs (14) are in green and putative
ESRs (16) are in brown below the sequence. The ﬁrst nucleotide of octamer PESEs with the P and I scores above 2.88 (14) are underlined. The FAS-
ESS hex3 set (10,32) is underlined in red. (C) Nucleotide sequences of the wild-type (WT) and mutated (2–17) splicing reporter constructs. Mutations
are in bold and underlined. Nucleotides identical to the wild-type are denoted by a dash. (D) Relative expression of exon 2-containing INS mRNA
isoforms. The splicing pattern of the WT and mutated (lanes 2–17) constructs is shown in the lower panel. Alternatively spliced products are shown
on the left and correspond to numbers shown in panel A. Utilization (percent) of each isoform is shown in the upper panel. Error bars indicate
standard deviations of a single transfection experiment in triplicate. (E) Subphysiological temperatures activate cryptic 30ss +36 and +126 in exon 3
and promotes splicing of intron 1 in the wild-type minigene. The cryptic 30ss (20) are denoted by arrows in panel A. Relative representation of RNA
isoforms 1 and 2 that lack exon 1 was not altered (data not shown), whereas isoforms 5 and 6 were less abundant. (F) Proinsulin secretion by 293T
cells following transfection of the wild-type (WT) and mutated constructs 8 and 12. Mutations are shown in panel C.
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presence (clone 3) of FAS-ESS GTGGGCA, which may
inhibit proximal 30ss, or to more extensive alterations
upstream of cryptic 30ss (clone 11).
The strongest predicted FAS-ESS (GGAGGGGT) is
human-speciﬁc as this motif is eliminated by a T variant
present in other primates and rodents (shown by a red
asterisk in Figure 8B). A G>T mutation at this position
in clone 7 promoted canonical splicing. A point mutation
at another non-conserved exon position (clone 8) also
improved utilization of the natural 30ss, while removing a
predicted FAS-ESS containing a run of ﬁve Gs. Mutation
in clone 9, which eliminated the ﬁrst exonic FAS-ESS,
had a similar eﬀect. Apart from FAS-ESSs, the increased
utilization of canonical 30ss in this reporter can be
explained by the removal of a competing AG dinucleotide
8nt downstream, although this distance may be too long
for eﬃcient competition (40,43). The inﬂuence of a
decoy 30ss on 30ss selection (30ss +36, Figure 8B–D, 20)
is illustrated by an increased canonical splicing in clone 10,
in which this 30ss was inactivated by mutation.
Interestingly, activation of a minor cryptic 30ss +36 was
not observed for any of the above mutations even after a
high number of PCR cycles. Transcripts spliced to this 30ss
were found in  0.1% expressed sequence tags from an
insulinoma library and were also detected in a pancreatic
mRNA sample (20). In an attempt to induce this 30ss,
we stressed transfected 293T cells by subphysiological
temperatures, which often activate aberrant splicing
(44,45). Low temperatures activated the cryptic 30ss +36
and also increased utilization of the cryptic 30ss +126
(Figure 8E).
Combinatorial effects ofFAS-ESSs on 3’ss selection
Choice of a proximal or distal splice site driven by inter-
vening auxiliary splicing signals may reﬂect their position
in the pre-mRNA, rather than their categorization as
enhancers or silencers (16,39,46). To test whether ESSs
retain their inhibitory eﬀects on intron-proximal 30ss when
stronger silencer is replaced by a weaker one in their
original positions and vice versa, we swapped two FAS-
ESSs that are located in the central region between
competing 30ss (clones 11–13). In clone 11, a strong intron-
proximal FAS-ESS was replaced by a weaker intron-distal
FAS-ESS, resulting in duplication of the latter. Clone 12
had a duplicated version of the stronger, intron-proximal
FAS-ESS instead of the intron-distal FAS-ESS and a
double mutation in clone 13 exchanged positions of the
Figure 9. Silencer-mediated inhibition of intron-proximal 30ss of LIPC
intron 2. (A) Schematic representation of the LIPC splicing reporter.
Exons, introns and aberrant splicing patterns are denoted as in
Figure 8. Aberrant 30ss 78 and 13nt upstream of canonical (can.) 30ss
of intron 1 are designated by numbers. Blue and red boxes indicate
sequences shown in panels B and C, respectively. Thick grey line
represents an intronic segment retained in the mature mRNA
transcribed from constructs carrying mutation IVS1-14A>G.
(B) Splicing pattern of LIPC minigenes mutated upstream of the
newly created 30AG (highlighted in blue). Clone designation (S&Sn,
where n is the approximate Shapiro–Senapathy score of the aberrant
30ss 13nt upstream of the authentic 30ss) and mutations are shown on
the left and the resulting RNA products on the right. The percentage of
the canonically spliced isoform is designated with %can. The identity of
each RNA product is shown at the top. IR2, retention of intron 2; ES2,
skipping of exon 2. (C) Splicing pattern of LIPC minigenes mutated in
a putative FAS-ESS (highlighted in red). Clone designation and
mutations are shown on the left. RNA products of minigenes  14G
and S&S63 (see panel B) are shown on the right. (D) Relative mRNA
expression of wild-type (WT) and mutated (ESS1-14) clones lacking
intron 2. Canonical products (can.) are shown in red and the amount of
splicing to aberrant 30ss  13 and  78 in white and grey, respectively.
6408 Nucleic Acids Research, 2007, Vol. 35, No. 19two ESSs. Single mutants (clones 11 and 12) did not create
or eliminate any predicted ESEs/ESSs, but clone 13 lost
one natural PESE and had one extra ESR. Canonical
splicing in clone 11 was increased (Figure 8D), indicating
that replacement of the stronger ESS with the weaker ESS
moderated inhibition of intron-proximal 30ss. In contrast,
canonical splicing was repressed in clone 12, indicating
that the presence of duplicated stronger ESSs was more
inhibitory for intron-proximal 30ss than in the wild-type
construct. Swapping intron-distal and intro-proximal
ESSs in clone 13 had no eﬀect. Clone 14, in which the
strong overlapping FAS-ESS was moved to an adjacent
position in place of an octamer PESE while removing
a predicted RESCUE-ESE further downstream markedly
increased splicing to the cryptic 30ss. In clone 15, the
overlapping FAS-ESSs were exchanged with an upstream
PESE, also promoting cryptic 30ss activation. Finally,
single- (clone 16) or double-nucleotide (clone 17) muta-
tions in predicted RESCUE-ESE had no or only minor
eﬀects.
As transiently transfected 293T cells are capable of
secreting the gene product (20), we examined the eﬀects
of FAS-ESS mutations on the proinsulin production by
measuring total proinsulin levels in culture supernatants.
We employed clones 8 and 12 (Figure 8F), in which
mutations did not alter amino acid sequences. Proinsulin
levels were higher in clone 8 and somewhat lower in clone
12 than in the wild-type, roughly reﬂecting the relative
expression of canonical isoform 4 (cf. Figure 8D and F),
indicating that mutations in exonic splicing auxiliary
signals can alter peptide production at the level of pre-
mRNA splicing.
Activation of 3’ss by upstream poly(G) element associated
withexon skipping
To test whether predicted auxiliary elements have similar
eﬀects on selection of an intronic cryptic 30ss, we employed
a minigene containing exons 1–3 of the human LIPC gene
(Figure 9A). Here, the aberrant 30ss was activated in the
ﬁrst intron 78nt upstream of the authentic intron/exon
junction and resulted from a disease-causing point
mutation IVS1-14A>G that created a new AG dinucleo-
tide downstream of the BPS (27,47). To identify cis-
elements that may restore canonical splicing and to
investigate utilization of competing splice sites upstream
(30ss  78) and downstream (30ss  13) of the BPS, we ﬁrst
introduced a progressively increasing number of purines
upstream of the newly created 30ss. The mutant constructs
had a varying strength of the 30ss  13, with a wide range
of the ME ( 1.55 to  9.31) and the S&S (65.8 to 46.3)
scores (Figure 9B).
The increasing number of As between position  18 to
 26 correlated positively with the amount of splicing
to the authentic 30ss (r=0.82, P<10
 15, Spearman rank
order test, Figure 9B). Although As upstream of the
aberrant 30ss  13 are likely to weaken its PPT, the newly
introduced As may also bring in additional consensus
BPSs and generally promote 30ss selection if located within
an optimal distance from the authentic 30ss (Figure 9B).
This interpretation seems to be supported by zero
utilization of authentic 30ss following a replacement of
the wild-type sequence by a stretch of Cs or Gs and
activation of 30ss  13 in clone S&S50CT, in which
putative branch point As were mutated. Surprisingly,
the introduction of a stretch of nine Gs upstream of the
aberrant 30ss  13 in clone S&S45 promoted use of this
30ss while inducing signiﬁcant exon skipping (Figure 9B).
This mutation minimized the predicted strength of 30ss
 13 by eliminating its upstream PPT, yet it did not
prevent potent activation of this splice site.
To test whether ESSs between competing 30ss  13 and
 78 consistently repress use of the intron-proximal site
in a suprabranch location, we mutated minigenes IVS-14G
and S&S63 in a strong predicted FAS-ESS (shown in red
in Figure 9C). Point mutations in clones 1 and 2 elimi-
nated this ESS, but did not create any predicted ESEs.
Mutations in clones 3 and 4 replaced the ESS with
adjacent ESEs located upstream (GAGAAG; clone 3) and
downstream (GATGAA; clone 4), duplicating the ESE
elements. In clone 5, the original ESS was replaced by
a weaker ESS GTGGCA. Examination of the resulting
splicing patterns revealed that utilization of 30ss  78 was
promoted in all clones, consistent with a relief from the
FAS-ESS-mediated repression of the intron-proximal 30ss
 78. In contrast, tandem duplication of this element in
clone 6 repressed the 30ss  78 almost completely, whereas
this 30ss was strongly promoted by mutations in clone 7
that created a tandem ESE GAAGAC. Double mutations
in clone 8, in which the FAS-ESS was swapped with the
upstream ESE GAAGAC, promoted use of the 30ss  78.
In clones 9–14, the ESS GGAGGG was replaced in the
original position by representative FAS-ESSs from groups
A, B, C, D/E, F and G (32), respectively. With the
exception of clone 9, all constructs consistently promoted
use of distal 30ss, either the 30ss  13 in constructs derived
from IVS-14G or both the  13 and canonical 30ss in
mutants derived from S&S63 (Figure 9C and D). The
strongest eﬀect was observed for the FAS-ESS group B
(clone 10), with a repressive hierarchy of B>F G>D/
E>C on the 30ss  78. Utilization of the authentic 30ss and
the 30ss  13 was approximately equal for all mutations
created in construct S&S63, consistent with the use of the
same BPS for both 30ss.
DISCUSSION
This work shows the ﬁrst systematic evaluation of auxi-
liary splicing sequences in the development of mutation-
induced aberrant splice sites. Our results clearly
demonstrate that a decision to include or exclude
sequences adjacent to splicing mutations in mature
transcripts is inﬂuenced by their ESS/ESE frequencies
(Figure 2). We show this both for exonic and intronic
segments and both for cryptic and de novo splice sites.
Rather than a traditionally perceived ‘binary’ concept of
exon inclusion and exclusion in the mRNA, these results
provide evidence for the existence of a gradient in exon
and intron deﬁnition at the level of pre-mRNA splicing
(Figures 2 and 4A). The observed intermediate levels of
ESSs/ESEs in newly included or excluded mRNAs are
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levels in extended segments of alternatively spliced exons
(48) and high levels of alternative splicing in humans (49).
They also reinforce the notion that it is the continuous
exonic and intronic DNA sequence that stores informa-
tion critical for correct intron removal (Figures 2 and 4A)
and accurate quantitative expression of the gene product
(Figure 8F). Signals carrying this information contribute
signiﬁcantly to a ‘splicing code’ (50), which is constituted
by combinations of regulatory elements in pre-mRNAs
and cellular complements of splicing factors. This code
controls phenotypic consequences of splicing mutations in
disease genes and locus-speciﬁc mutation patterns.
Systematic comparison of the ESS/ESE densities
between exonic sequences excluded from mature tran-
scripts and average exons revealed greater diﬀerences
in the ESS densities than ESE densities, particularly in
the PESS levels (Table 1, Figure 2). This ﬁnding is in
agreement with recent observations of a more pronounced
eﬀect on splicing of ESSs than ESEs (28,32). The hier-
archy of IN-PS>DN-I PS>50UTR-IL>CR-I>DN-E
>CR-E>EXSK>ALT-EX>HM-EX>NC-EX in the
PESS density was comparable to that observed for FAS-
ESSs. Although the PESS density was biased towards
sequences that were originally used for their selection
(Figure 2A and B), these elements showed also greater
diﬀerences between CR-I/DN-I and average introns
than the remaining tested elements. In agreement with
our data, PESSs showed the most signiﬁcant overlap with
auxiliary signals recently identiﬁed by a novel machine-
learning algorithm (51).
Comparison of the intrinsic strength of pseudoexon
30 and 50ss (Figure 5) provided statistical support for a
mechanism whereby a strong de novo donor or acceptor
site is critical to drive the inclusion of newly recognized
exons. This is consistent with a recent observation that
exons with alternatively spliced 30 or 50ss have an intrin-
sically strong splice site on the ﬁxated exon side (48) and
with previous case reports (52). Once a strong anchor is
introduced by mutation, exonization of intronic segments
is more likely to proceed to full inclusion in the mRNA,
and presumably to a more severe disease phenotype, if
their ESE densities are higher and their ESS densities
lower than in average introns (Figure 2). The observed
second highest SRp40 ESE density in PS might suggest a
distinct requirement for this protein in exon deﬁnition,
in line with previous in vitro studies implicating only
SRp40 (53) or only SRp40/SRp55 (54) in exon inclusion,
but not the remaining SR proteins. Apart from the diﬀer-
ential splice-site strength and ESE/ESS density, the RNA
secondary structure has been recently shown to be a
key feature of cryptic exon activation in the ATM and
CFTR genes (55). Thus, this small but rapidly expanding
sequence category may provide a useful resource for dis-
secting factors that inﬂuence exonization without reliance
on a pre-existing splice site.
Exons that were skipped as a result of splice-site
mutations were weaker than average exons, suggesting
that such mutations are more likely to result in phenotypic
consequences than the same mutations ﬂanking stronger
exons. The observed lower intrinsic strength of 30ss in
wild-type EXSK sequences as compared to HM-EX and
ALT-EX sequences (Figure 6B) may reﬂect a special role
of 30ss in exon deﬁnition. Interestingly, an increase in the
splice-site strength with growing intron size in evolution
was more prominent for 30ss than 50ss (56,57). In addition
to the splice-site strength, skipped exons oﬀered both the
inferior choice of decoy splice sites and the diminished
chance to select them in shorter target sequences as
compared to CR-E exons (Tables 1 and 2). Together with
the higher SF2/ASF ESE and reduced ESS densities
(Figure 2 and Tables 1 and 2), these four variables were
key determinants of a decision to choose either a cryptic
splice site in the exon or to opt for its exclusion from the
mRNA. Although the remaining sequence-based predictor
variables in logistic regression did not show signiﬁcant
P-values (cf. Tables 1 and 2), they are by no means
excluded from future models with updated datasets. Better
score matrices for the remaining SR proteins may improve
the model even if their individual eﬀects on exon inclusion
and splice-site activation are smaller than SF2/ASF.
Likewise, extending sequence coverage beyond the inter-
vening segments with an enlarged DBASS3/5 sample may
capture additional signals. Because the predictive value
of suﬃciently long individual sequences is signiﬁcant
(Figure S2), our results will also facilitate the development
of publicly available algorithms that compute the like-
lihood of activating aberrant splice sites in exons as
opposed to exon skipping if authentic splice sites are
eliminated by mutation (I.V. et al., in preparation).
The smaller peak of the EXSK exon size distribution
(Figure 6A) was largely due to frequent skipping of 54-nt
exons (n=19) of the collagen genes. These exons are rich
in FAS-ESSs, but had only two PESSs (AGAATGGT,
AGGATGGG). Inspection of 60 FAS-ESS hexamers
identiﬁed in EXSK showed that about half of them
contained GGG triplets and virtually all had two conse-
cutive Gs, with TCCTGG, CCTGGG and GATGGG
being the most frequent FAS-ESSs (Table S5). A subset of
these hexamers contained optimal binding sites for
hnRNP A1 (UAGGGU or UAGGGA) (4) or G-rich
motifs implicated in exon silencing or intron exonization,
often reﬂecting their relative location from authentic splice
sites (39,46,58,59). Some of the collagen exons that were
skipped as a result of splicing mutations had an extra-
ordinary density of FAS-ESSs. For example, the mean
FAS-ESS density of COL6A1 exon 14 (60), COL1A1 exon
49 (61) and COL3A1 exon 37 (62) was 18.52, 12.96 and
11.11, respectively, with the latter exon completely lacking
RESCUE-ESEs. The intrinsic strength of 30 and 50ss of
54-nt exons was not signiﬁcantly diﬀerent from the
average exon (data not shown), suggesting that their
propensity to exon skipping is largely due to the small
exon size and increased numbers of FAS-ESSs. These
features may have contributed to the extraordinary
evolution of collagen genes, which are characterized by
multiple 54-nt exons encoding Gly-X1-X2 triplets in the
helical domain (63). These exons were occasionally
duplicated or triplicated, possibly through partially
processed RNAs (63).
Of four tested SR matrices, SF2/ASF gave the best
discrimination of newly intronized and exonized sequence
6410 Nucleic Acids Research, 2007, Vol. 35, No. 19categories and the largest spread across the exon-intron
spectrum (Figure 4A and Table S4). This is consistent with
the lowest P-values observed for SF2/ASF of the four
proteins when comparing SR ESE motif frequencies in
exons and introns (42). The elevated SF2/ASF ESE levels
between cryptic 50ss and their authentic counterparts as
compared to de novo 50ss and average exons (Figures 4B
and 7) suggests that they compensate the relative lack of
splicing silencers in 50ss CR-E (Figure 3E). They may also
explain a previous observation of more pronounced eﬀects
of ESEs on competing 50ss than 30ss (32). As SF2/ASF
ESEs and high-score PESEs signiﬁcantly overlap (33) and
FAS-hex3 are enriched in alternative 50 exons (10), future
studies with a higher number of 50ss CR-E sequences
should determine a spatial relationship between these
elements and estimate to what extent the observed 50 to
30ss bias can be explained by greater availability of decoy
50ss than 30ss in CR-E exons (Table 1). Reduced availabi-
lity of 50ss recognition sequences in the vicinity of exons
that were skipped has been recently noticed for NF1 (28)
and other genes (18). Nevertheless, dominant contribution
of the 50ss NN score density to diﬀerences in the overall
NN score density is likely to reﬂect greater sequence
constraints imposed by the BPS-PPT-30YAG signals than
by the less extensive 50ss consensus.
Our experimental data conﬁrm and extend the previous
ﬁnding (32) that FAS-ESSs consistently inhibit intron-
proximal splice sites. The only exception was the FAS-ESS
group A (TTCGTT; Figure 9), which showed the weakest
eﬀect of all representative FAS-ESS with other reporters
(32). In our experiments, the inhibitory eﬀects of predicted
FAS-ESSs on intron-proximal 30ss were retained if these
elements were maintained at their original positions in
the pre-mRNA and were predictably modiﬁed by combin-
ing the auxiliary signals in a modular, possibly additive
manner and by removing a decoy 30AG nearby. Our
unexpected observation of signiﬁcant utilization for newly
created AGs in the AG exclusion zone in the unfavourable
context of a preceding stretch of Gs (Figure 9B) can be
mechanistically explained by creating a secondary struc-
ture altering accessibility of spliceosomal complexes,
by elimination of the authentic BPS that weakens exon
deﬁnition and leads to exons skipping, by introduction of
strong ESSs that completely repress the intron-proximal
30ss  78, most likely through factors that bind to poly(G)
elements, such as hnRNP H/H0/F (3,5,39,46), and activate
distal the 30ss  13, or by a combination of these factors.
In conclusion, in vivo selection of aberrant splice sites in
introns and exons is extensively controlled by auxiliary
splicing signals. Exonic sequences that are excluded from
the mRNA as a result of mutations activating aberrant
splice sites have more ESSs and less ESEs than average
conserved exons. Conversely, intronic sequences that are
included in the mRNAs have more ESEs and less ESSs
than average introns. Second, eﬃcient use of intrinsically
weak cryptic splice sites in exons is facilitated by a higher
than average density of ESSs, which promote activation
of intron-distal sites, particularly cryptic 30ss (Figures 2
and 3E), and a high density of SF2/ASF ESE motifs,
especially for cryptic 50ss (Figures 4B and 7). Third, exons
that are skipped as a result of splice-site mutations are
smaller than typical exons ( 90% of the median length of
conserved exons), have weaker 30ss ( 95% of the median
ME score), higher than average density of predicted
ESSs and lower than average density of ESEs. Fourth, a
decision to exclude the whole exon or activate exonic
aberrant splice site if one of the authentic splice sites is
inactivated by mutation is largely driven by the overall
availability of intrinsically strong decoy splice sites, SF2/
ASF support and the balance between the ESS density in
sequences between authentic and aberrant splice sites and
the remaining exonic sequences. Fifth, predicted ESSs can
promote eﬃcient selection of 30ss in a highly unfavourable
context, highlighting the power of auxiliary sequences to
control selection of many intrinsically weak splice sites in
the genome. Finally, altered 30ss selection through muta-
tions in predicted ESSs and the resulting quantitative
changes in canonical mRNAs and peptide production
reinforce the notion that alternative splicing is an impor-
tant but underappreciated mechanism of ﬁne-tuning gene
expression and that gene variants located in these elements
are likely to contribute signiﬁcantly to inter-individual
phenotypic variability.
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